These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 10498590)

  • 1. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
    Curtis RE; Travis LB; Rowlings PA; Socié G; Kingma DW; Banks PM; Jaffe ES; Sale GE; Horowitz MM; Witherspoon RP; Shriner DA; Weisdorf DJ; Kolb HJ; Sullivan KM; Sobocinski KA; Gale RP; Hoover RN; Fraumeni JF; Deeg HJ
    Blood; 1999 Oct; 94(7):2208-16. PubMed ID: 10498590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation.
    Lynch BA; Vasef MA; Comito M; Gilman AL; Lee N; Ritchie J; Rumelhart S; Holida M; Goldman F
    Bone Marrow Transplant; 2003 Sep; 32(5):527-33. PubMed ID: 12942101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
    Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ
    Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients.
    Martin PJ; Rowley SD; Anasetti C; Chauncey TR; Gooley T; Petersdorf EW; van Burik JA; Flowers ME; Storb R; Appelbaum FR; Hansen JA
    Blood; 1999 Oct; 94(7):2192-9. PubMed ID: 10498588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.
    Champlin RE; Passweg JR; Zhang MJ; Rowlings PA; Pelz CJ; Atkinson KA; Barrett AJ; Cahn JY; Drobyski WR; Gale RP; Goldman JM; Gratwohl A; Gordon-Smith EC; Henslee-Downey PJ; Herzig RH; Klein JP; Marmont AM; O'Reilly RJ; Ringdén O; Slavin S; Sobocinski KA; Speck B; Weiner RS; Horowitz MM
    Blood; 2000 Jun; 95(12):3996-4003. PubMed ID: 10845940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
    Spencer A; Szydlo RM; Brookes PA; Kaminski E; Rule S; van Rhee F; Ward KN; Hale G; Waldmann H; Hows JM; Batchelor JR; Goldman JM
    Blood; 1995 Nov; 86(9):3590-7. PubMed ID: 7579468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.
    Gupta V; Ball SE; Yi QL; Sage D; McCann SR; Lawler M; Ortin M; Freires M; Hale G; Waldmann H; Gordon-Smith EC; Marsh JC
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):867-76. PubMed ID: 15570255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
    Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
    Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.
    Socié G; Curtis RE; Deeg HJ; Sobocinski KA; Filipovich AH; Travis LB; Sullivan KM; Rowlings PA; Kingma DW; Banks PM; Travis WD; Witherspoon RP; Sanders J; Jaffe ES; Horowitz MM
    J Clin Oncol; 2000 Jan; 18(2):348-57. PubMed ID: 10637249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Landgren O; Gilbert ES; Rizzo JD; Socié G; Banks PM; Sobocinski KA; Horowitz MM; Jaffe ES; Kingma DW; Travis LB; Flowers ME; Martin PJ; Deeg HJ; Curtis RE
    Blood; 2009 May; 113(20):4992-5001. PubMed ID: 19264919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome.
    Green A; Clarke E; Hunt L; Canterbury A; Lankester A; Hale G; Waldmann H; Goodman S; Cornish JM; Marks DI; Steward CG; Oakhill A; Pamphilon DH
    Blood; 1999 Oct; 94(7):2236-46. PubMed ID: 10498594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
    Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F
    Blood; 1994 Apr; 83(7):1980-7. PubMed ID: 8142664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation.
    Min CK; Kim DW; Lee JW; Min WS; Kim CC
    Acta Haematol; 2000; 104(4):185-92. PubMed ID: 11279309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
    Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
    Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.